Across TCGA pan-cancer cohorts, MIR4421 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of MIR4421’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where MIR4421 RNA is repressed in tumor relative to normal tissue. In most cancer types MIR4421 is over-expressed in tumor, although a few such as BRCA show the opposite, repressed pattern.
BRCA and PRAD are the cancer types where MIR4421 tumor–normal differential expression is most reproducible.